{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:49:21Z","timestamp":1790009361714,"version":"4.0.1"},"reference-count":59,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,8,25]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal dosing regimen for immune checkpoint blockade (ICB) remains a critical question in oncology. Although immune-related adverse events (irAEs) are common with ICB, the incidence and severity of irAEs following a single dose of anti-programmed death-ligand 1 (PD-(L)1) blockade have not yet been investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-center prospective cohort study at Gustave Roussy (Villejuif, France), based on a population of patients with advanced or metastatic cancer, using data from the French Registre des Effets Ind\u00e9sirables S\u00e9v\u00e8res des Anticorps Monoclonaux (REISAMIC) registry, a pharmacovigilance database dedicated to irAEs. Between December 2014 and December 2023, we included adults with solid or hematologic malignancies who presented with irAEs after the first infusion of anti-PD-(L)1 therapy, regardless of the treatment indication, and before the administration of the second dose of ICB. The main outcomes included the incidence and characteristics of irAEs, particularly severe (grade 3\u20134) and fatal (grade 5) events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 3565 patients prospectively followed in REISAMIC, 70 (1.96%) experienced irAEs following a single infusion. Of these 70 patients, severe irAEs (grade 3\u20134) occurred in 20 patients (37.1%), and fatal irAEs (grade 5) were recorded in three cases (4.3%), indicating significant toxicity risks. The most frequently affected organ systems were the skin (14 (20%)), musculoskeletal system (11 (15.7%)), endocrine system (9 (12.9%)), and cardiovascular system (9 (12.9%)). Most irAEs developed within 20 days after treatment, with a median onset time of 14 days (IQR, 5\u201321). Multiorgan toxicities were observed in 10% of patients. Despite the severity, no predictive markers for fatality, multiorgan involvement, or early onset were identified, including pre-existing autoimmune conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study underscores the notable risk of severe and fatal irAEs following a single dose of anti-PD-(L)1 therapy in patients with advanced\/metastatic cancer. The absence of predictive markers for fatality, multiorgan toxicities, or early onset highlights the need for enhanced patient monitoring during the initial treatment phase. Further research is needed to optimize dosing regimens, balancing safety and efficacy for safer clinical use of immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012756","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:25:28Z","timestamp":1758691528000},"page":"e012756","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1978-4320","authenticated-orcid":false,"given":"Romain","family":"Guitton","sequence":"first","affiliation":[{"name":"Internal Medicine and Clinical Immunology, Nancy University Hospital Center, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8275-7044","authenticated-orcid":false,"given":"Ariane","family":"Laparra","sequence":"additional","affiliation":[{"name":"Gustave Roussy Interdisciplinary Department of Supportive Care forOnco-Haematology Patients, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1019-8076","authenticated-orcid":false,"given":"Noemie","family":"Chanson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, and Clinical Immunology, AP-HP Universit\u00e9 Paris Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Champiat","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-064X","authenticated-orcid":false,"given":"Francois-Xavier","family":"Danlos","sequence":"additional","affiliation":[{"name":"Drug Development Department, INSERM U1015, Universit\u00e9 Paris Saclay, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3482-3331","authenticated-orcid":false,"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[{"name":"Drug Development Department, INSERM U1015, Universit\u00e9 Paris Saclay, Gustave Roussy, Villejuif, France"},{"name":"INSERM U1170, Department of Hematology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-4941","authenticated-orcid":false,"given":"Sabine","family":"Messayke","sequence":"additional","affiliation":[{"name":"Drug Development Department, INSERM U1015, Universit\u00e9 Paris Saclay, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aurelien","family":"Marabelle","sequence":"additional","affiliation":[{"name":"Drug Development Department, INSERM U1015, Universit\u00e9 Paris Saclay, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4425-8516","authenticated-orcid":false,"given":"Olivier","family":"Lambotte","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, and Clinical Immunology, AP-HP Universit\u00e9 Paris Saclay, Le Kremlin-Bic\u00eatre, France"},{"name":"Inserm, CEA, UMR1184 IDMIT, Universit\u00e9 Paris-Saclay Facult\u00e9 de M\u00e9decine, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2026052108452912000_13.9.e012756.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2026052108452912000_13.9.e012756.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2026052108452912000_13.9.e012756.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2026052108452912000_13.9.e012756.4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jamiaopen\/ooy045","article-title":"Immunotherapy-related adverse events (irAEs): extraction from FDA drug labels and comparative analysis","volume":"2","author":"Wang","year":"2019","journal-title":"JAMIA Open"},{"key":"2026052108452912000_13.9.e012756.5","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.790"},{"key":"2026052108452912000_13.9.e012756.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026052108452912000_13.9.e012756.7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.revmed.2021.01.002","article-title":"Gestion des toxicit\u00e9s induites par les inhibiteurs de checkpoint immunologique : donn\u00e9es de la r\u00e9union de concertation pluridisciplinaire \u00ab ToxImmun \u00bb en Occitanie Est","volume":"42","author":"Rivet","year":"2021","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"2026052108452912000_13.9.e012756.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1167"},{"key":"2026052108452912000_13.9.e012756.9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026052108452912000_13.9.e012756.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.08.048"},{"key":"2026052108452912000_13.9.e012756.11","doi-asserted-by":"crossref","first-page":"906251","DOI":"10.3389\/fonc.2022.906251","article-title":"Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"2026052108452912000_13.9.e012756.12","doi-asserted-by":"crossref","first-page":"101204","DOI":"10.1016\/j.currproblcancer.2025.101204","article-title":"Dosing immune-checkpoint inhibitors: Opportunities for the future","volume":"57","author":"Jeon","year":"2025","journal-title":"Curr Probl Cancer"},{"key":"2026052108452912000_13.9.e012756.13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/djad061","article-title":"Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study","volume":"115","author":"Cantini","year":"2023","journal-title":"JNCI"},{"key":"2026052108452912000_13.9.e012756.14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cllc.2021.12.005","article-title":"Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic","volume":"23","author":"Hijmering-Kappelle","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026052108452912000_13.9.e012756.15","doi-asserted-by":"crossref","unstructured":"Sehgal K , Costa DB , Rangachari D . Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will It Outlast the COVID-19 Pandemic? Front Oncol 2020;10. doi:10.3389\/fonc.2020.01193","DOI":"10.3389\/fonc.2020.01193"},{"key":"2026052108452912000_13.9.e012756.16","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/j.cllc.2020.05.028","article-title":"Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer","volume":"22","author":"Sehgal","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"2026052108452912000_13.9.e012756.17","doi-asserted-by":"crossref","unstructured":"Wages NA , Chiuzan C , Panageas KS . Design considerations for early-phase clinical trials of immune-oncology agents. J Immunotherapy Cancer 2018;6. doi:10.1186\/s40425-018-0389-8","DOI":"10.1186\/s40425-018-0389-8"},{"key":"2026052108452912000_13.9.e012756.18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2021.01.048","article-title":"Immune-related adverse events after a single dose of pembrolizumab","volume":"148","author":"Vos","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026052108452912000_13.9.e012756.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2026052108452912000_13.9.e012756.20","doi-asserted-by":"crossref","first-page":"113542","DOI":"10.1016\/j.ejca.2024.113542","article-title":"Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study","volume":"199","author":"Mandal\u00e0","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026052108452912000_13.9.e012756.21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00258","article-title":"Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis","volume":"10","author":"Park","year":"2020","journal-title":"Front Oncol"},{"key":"2026052108452912000_13.9.e012756.22","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/s41591-022-02029-1","article-title":"Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access","volume":"28","author":"Hirsch","year":"2022","journal-title":"Nat Med"},{"key":"2026052108452912000_13.9.e012756.23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1748982","article-title":"Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis","volume":"9","author":"Shulgin","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026052108452912000_13.9.e012756.24","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.185777"},{"key":"2026052108452912000_13.9.e012756.25","article-title":"Multiple Autoimmune Complications After a Single Dose of Pembrolizumab","volume":"15","author":"Ahdi","year":"2023","journal-title":"Cureus"},{"key":"2026052108452912000_13.9.e012756.26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.621858","article-title":"Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"2026052108452912000_13.9.e012756.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"},{"key":"2026052108452912000_13.9.e012756.28","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.1200\/JCO.2024.42.16_suppl.8645","article-title":"Comparing rates of immune checkpoint inhibitor toxicity in different treatment settings (neoadjuvant, adjuvant, and palliative) in non-small cell lung cancer (NSCLC): A meta-analysis of phase III clinical trials","volume":"42","author":"Moloney","year":"2024","journal-title":"JCO"},{"key":"2026052108452912000_13.9.e012756.29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016\u20132019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026052108452912000_13.9.e012756.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2026052108452912000_13.9.e012756.31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002553","article-title":"Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis","volume":"9","author":"Puzanov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052108452912000_13.9.e012756.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2026052108452912000_13.9.e012756.33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.830631","article-title":"Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1\/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism","volume":"13","author":"Yin","year":"2022","journal-title":"Front Immunol"},{"key":"2026052108452912000_13.9.e012756.34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0174"},{"key":"2026052108452912000_13.9.e012756.35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026052108452912000_13.9.e012756.36","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.47649","article-title":"Patient, Caregiver, and Clinician Perspectives on the Time Burdens of Cancer Care","volume":"7","author":"Gupta","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026052108452912000_13.9.e012756.37","doi-asserted-by":"crossref","first-page":"151545","DOI":"10.1016\/j.soncn.2023.151545","article-title":"The Role of Nurses in the Management of Adverse Events in Patients Receiving First-Line Axitinib Plus Immuno-Oncology Agents for Advanced Renal Cell Carcinoma","volume":"40","author":"Parreira","year":"2024","journal-title":"Semin Oncol Nurs"},{"key":"2026052108452912000_13.9.e012756.38","first-page":"271","article-title":"Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients","volume":"23","author":"Wood","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"2026052108452912000_13.9.e012756.39","doi-asserted-by":"crossref","first-page":"879900","DOI":"10.3389\/fimmu.2022.879900","article-title":"Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"2026052108452912000_13.9.e012756.40","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026052108452912000_13.9.e012756.41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-52034-2","article-title":"Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study","volume":"14","author":"Feng","year":"2024","journal-title":"Sci Rep"},{"key":"2026052108452912000_13.9.e012756.42","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70324","article-title":"Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta-Analysis","volume":"13","author":"Xu","year":"2024","journal-title":"Cancer Med"},{"key":"2026052108452912000_13.9.e012756.43","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026052108452912000_13.9.e012756.44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CJI.0000000000000377","article-title":"Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases","volume":"44","author":"Yeung","year":"2021","journal-title":"J Immunother"},{"key":"2026052108452912000_13.9.e012756.45","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1016\/S2665-9913(23)00064-4","article-title":"Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study","volume":"5","author":"McCarter","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2026052108452912000_13.9.e012756.46","doi-asserted-by":"crossref","first-page":"114148","DOI":"10.1016\/j.ejca.2024.114148","article-title":"A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease","volume":"207","author":"Lopez-Olivo","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026052108452912000_13.9.e012756.47","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac046"},{"key":"2026052108452912000_13.9.e012756.48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1399171","article-title":"Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness","volume":"14","author":"Olsson Ladjevardi","year":"2024","journal-title":"Front Oncol"},{"key":"2026052108452912000_13.9.e012756.49","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01671","article-title":"Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials","volume":"10","author":"Da","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026052108452912000_13.9.e012756.50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.625872","article-title":"The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease","volume":"11","author":"Tang","year":"2021","journal-title":"Front Oncol"},{"key":"2026052108452912000_13.9.e012756.51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026052108452912000_13.9.e012756.52","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343"},{"key":"2026052108452912000_13.9.e012756.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.010"},{"key":"2026052108452912000_13.9.e012756.54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.trsl.2015.06.005","article-title":"Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma","volume":"166","author":"Quirk","year":"2015","journal-title":"Transl Res"},{"key":"2026052108452912000_13.9.e012756.55","doi-asserted-by":"publisher","DOI":"10.1038\/S41590-020-0769-3"},{"key":"2026052108452912000_13.9.e012756.56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"2026052108452912000_13.9.e012756.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2026052108452912000_13.9.e012756.58","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176567","article-title":"Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures","volume":"134","author":"Kao","year":"2024","journal-title":"J Clin Invest"},{"key":"2026052108452912000_13.9.e012756.59","doi-asserted-by":"crossref","first-page":"670391","DOI":"10.3389\/fimmu.2021.670391","article-title":"The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:45:42Z","timestamp":1779378342000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":59,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jitc-2025-012756"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012756","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}